Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Pharvaris announced that Phase 3 RAPIDe-3 results for oral deucrictibant IR in treating HAE attacks have been published in The Lancet, with the study meeting its primary endpoint and all 11 secondary endpoints with high statistical significance. Deucrictibant IR delivered symptom relief in a median 1.28 hours and complete symptom resolution in 11.95 hours, with a well-tolerated safety profile and consistent results across subgroups including laryngeal attacks.
Key figures
- Drug Name
- deucrictibant immediate-release (IR) capsule
- Phase Of Trial
- Phase 3
- Pdufa date
- April 23, 2027
- Secondary endpoints met
- 11
- Time to symptom relief hours
- 1.28
- Time to complete resolution hours
- 11.95
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.